PolyPid (NASDAQ:PYPD) Shares Down 0.8% - Should You Sell?

Key Points

• PolyPid shares fell 0.8% to $5.17 in midday trading, with volume down 60% from the average session. The stock remains above its 50-day and 200-day moving averages of $4.87 and $4.70.
• Analyst sentiment is broadly positive, with three Buy ratings and one Sell rating, producing a “Moderate Buy” consensus and an average price target of $11.33—more than double the current price.
• PolyPid reported a quarterly loss of $0.35 per share, beating the $0.38 consensus estimate, while institutional investors own 26.47% of the company after several funds initiated positions.

PolyPid Ltd. (NASDAQ:PYPD - Get Free Report)'s stock price dropped 0.8% during trading on Monday . The stock traded as low as $5.12 and last traded at $5.17. Approximately 40,643 shares changed hands during mid-day trading, a decline of 60% from the average session volume of 102,247 shares. The stock had previously closed at $5.21.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Craig Hallum set a $12.00 price objective on PolyPid in a research note on Wednesday, July 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $13.00 target price on shares of PolyPid in a research report on Tuesday, July 21st. Finally, Weiss Ratings upgraded PolyPid from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, June 23rd. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, PolyPid presently has an average rating of "Moderate Buy" and an average target price of $11.33.

PolyPid Trading Down 0.8%

The company's 50-day moving average price is $4.87 and its two-hundred day moving average price is $4.70. The company has a market cap of $98.64 million, a P/E ratio of -3.49 and a beta of 1.41.

PolyPid (NASDAQ:PYPD - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.03. As a group, analysts anticipate that PolyPid Ltd. will post -0.92 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of PYPD. AIGH Capital Management LLC acquired a new position in shares of PolyPid in the 2nd quarter worth approximately $7,644,000. ADAR1 Capital Management LLC acquired a new stake in shares of PolyPid during the 2nd quarter valued at approximately $528,000. Symmetry Peak Management LLC bought a new position in PolyPid during the second quarter worth $512,000. J. Goldman & Co LP bought a new position in PolyPid during the second quarter worth $504,000. Finally, Connective Capital Management LLC acquired a new position in PolyPid in the second quarter worth $343,000. Institutional investors own 26.47% of the company's stock.

About PolyPid

PolyPid Ltd. is an Israeli clinical-stage biopharmaceutical company developing locally administered therapies designed to provide controlled and sustained drug delivery at treatment sites. The company's proprietary PLEX polymer-lipid encapsulation matrix is intended to release therapeutic agents over an extended period, with the goal of improving treatment effectiveness and reducing the need for repeated systemic dosing.

PolyPid's lead product candidate is D-PLEX100, an investigational formulation containing doxycycline that is designed for administration at surgical sites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.